MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2147/cmar.s393729

Медицинская библиотека · Cancer management and research · 2023

Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.

Poh Mau Ern, How Soon Hin, Ho Gwo Fuang, Pang Yong Kek, Hasbullah Harissa H, Tho Lye Mun, Muhamad Nor Ibtisam, Lim Bee Chiu, Ho Kean Fatt, Thiagarajan Muthukkumaran, Samsudin Azlina, Omar Azza, Ong Choo Khoon, Soon Sing Yang, Tan Justin Yu Kuan, Zainal Abidin Muhammad Adil

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Anaplastic lymphoma kinase (ALK) inhibitors are associated with good overall survival (OS) for ALK-positive metastatic non-small cell lung cancer (NSCLC). However, these treatments can be unavailable or limited by financial constraints in developing countries. Using data from a nationwide lung cancer registry, the present study aimed to identify treatment patterns and clinical outcomes of ALK-positive NSCLC in Malaysia.

METHODS

This retrospective study examined data of patients with ALK-positive NSCLC from 18 major hospitals (public, private, or university teaching hospitals) throughout Malaysia between January 1, 2015 and December 31, 2020 from the National Cardiovascular and Thoracic Surgical Database (NCTSD). Data on baseline characteristics, treatments, radiological findings, and pathological findings were collected. Overall survival (OS) and time on treatment (TOT) were calculated using the Kaplan-Meier method.

RESULTS

There were 1581 NSCLC patients in the NCTSD. Based on ALK gene-rearrangement test results, only 65 patients (4.1%) had ALK-positive advanced NSCLC. Of these 65 patients, 59 received standard-of-care treatment and were included in the analysis. Crizotinib was the most commonly prescribed ALK inhibitor, followed by alectinib and ceritinib. Patients on ALK inhibitors had better median OS (62 months for first-generation inhibitors, not reached at time of analysis for second-generation inhibitors) compared to chemotherapy (27 months), but this was not statistically significant (P=0.835) due to sample-size limitations. Patients who received ALK inhibitors as first-line therapy had significantly longer TOT (median of 11 months for first-generation inhibitors, not reached for second-generation inhibitors at the time of analysis) compared to chemotherapy (median of 2 months; P<0.01).

CONCLUSION

Patients on ALK inhibitors had longer median OS and significantly longer TOT compared to chemotherapy, suggesting long-term benefit.

Для цитирования: Poh Mau Ern, How Soon Hin, Ho Gwo Fuang, Pang Yong Kek, Hasbullah Harissa H, Tho Lye Mun, Muhamad Nor Ibtisam, Lim Bee Chiu, Ho Kean Fatt, Thiagarajan Muthukkumaran, Samsudin Azlina, Omar Azza, Ong Choo Khoon, Soon Sing Yang, Tan Justin Yu Kuan, Zainal Abidin Muhammad Adil. Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.. Cancer management and research. 2023. DOI: 10.2147/cmar.s393729.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.